Kisspeptin (KISS1; encoded by Kiss1) neurons in the arcuate nucleus (ARC) coexpress tachykinin 3 (TAC3; also known as neurokinin B) and dynorphin A (PDYN). Accordingly, they are termed KNDy neurons and considered to be crucial in generating pulsatile release of gonadotropin-releasing hormone. Accumulating evidence suggests that Kiss1 and Tac3 are negatively regulated by estrogen. However, it has not been fully determined whether and how estrogen modulates Pdyn and PDYN. Here, we examined the expression of Pdyn mRNA and PDYN by in situ hybridization and immunohistochemistry, respectively, in the ARC of female rats after ovariectomy (OVX) and OVX plus low-or high-dose beta-estradiol (E 2 ) replacement. We also investigated the effect of E 2 on expression of Kiss1, KISS1, Tac3, and TAC3. Furthermore, colocalization of PDYN and estrogen receptor alpha (ESR1) was determined. Subsequently, we found that low-dose E 2 treatment had no effect on Pdyn mRNA-expressing cells, but increased PDYN-immunoreactive (ir) cell numbers. In contrast, high-dose E 2 treatment resulted in prominent reductions in both Pdyn mRNA-expressing and PDYN-ir cell numbers. Changes induced by low or high doses of E 2 were similarly observed in the expression of Kiss1, KISS1, Tac3, and TAC3. The majority of PDYN-ir neurons coexpressed ESR1 in all groups. Our results indicate that E 2 regulates the expression of PDYN, as well as KISS1 and TAC3, with regulation by E 2 differing according to its levels.
Introduction
In female mammals, gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) are controlled by negative and positive feedback systems of estrogen to maintain the reproductive cycle.
A major population of neurons expressing the Kiss1 gene and its protein product (KISS1) are located in the anteroventral periventricular nucleus (AVPV) and arcuate nucleus (ARC) of rodents. AVPV KISS1 is thought to be crucial for the preovulatory GnRH/LH surge via a positive feedback response to elevation of estradiol [1] . ARC KISS1 is involved in pulsatile GnRH secretion mediated by low estrogen levels [3] . Because KISS1 neurons in the ARC also express other neuropeptides, namely tachykinin 3 (TAC3; also known as neurokinin B and encoded by Tac3) and dynorphin A [PDYN; encoded by Pdyn (prodynorphin)], they are termed KNDy neurons [4, 5] . It has been suggested that the release of KISS1, which promotes pulsatile GnRH/LH releases, is influenced by the combined action of TAC3 and PDYN. Specifically, TAC3 autostimulates KISS1 release, while PDYN exerts an inhibitory action to terminate the pulse [6, 7] .
Regulation of KNDy neurons by sex steroids has been mainly evaluated at the mRNA level. It is well established that Kiss1 and Tac3 mRNA expression in the ARC undergoes similar changes in response to ovariectomy and steroid manipulation with mRNA expression levels of both genes increasing upon ovariectomy and decreasing upon estrogen replacement in mice, rats, and humans [2, [8] [9] [10] [11] [12] [13] [14] [15] . These findings suggest that estrogen suppresses mRNA expression of Kiss1 and Tac3 in the ARC. Nevertheless, an immunohistochemistry (IHC) study revealed that KISS1 and TAC3 are differentially regulated by estrogen. Ovariectomy increases the number of KISS1-immunoreactive (ir) cells, but it does not alter TAC3-ir cell numbers, whereas estrogen replacement increases TAC3-ir cells, but not KISS1-ir cells compared with ovariectomy [16] . Thus, there may be differences between the mRNA and protein levels of KISS1 and TAC3. Conversely, estrogen treatment reduces Pdyn mRNA levels in ovariectomized (OVX) female rats [2, 8] , suggesting that estrogen inhibits Pdyn mRNA expression in the ARC, as well as Kiss1 and Tac3 mRNA. However, opposing results show that the number of Pdyn mRNA-expressing cells in the ARC increases in estrogentreated OVX monkeys [17] and decreases in OVX ewes [18] , implying that estrogen facilitates Pdyn mRNA expression. Additionally, the number of Pdyn-expressing cells [quantified by in situ hybridization (ISH)] and Pdyn gene expression levels (semi-quantitatively analyzed by RT-PCR) do not differ in the ARC of OVX female rats with or without estrogen treatment [19] . Hence, no definitive conclusion can be reached with respect to the effect of estrogen on dynorphin gene expression, because the animal species and estrogen dosage differ in these studies. Moreover, no report has addressed estrogen-mediated changes in dynorphin protein levels in the ARC. Therefore, differences between dynorphin mRNA and protein levels also remain unclear.
Estrogen exerts its actions through classical nuclear estrogen receptor α (ESR1) and β (ESR2) [20] , although it has become evident that estrogen also mediates rapid nongenomic responses via extranuclear estrogen receptors or membrane-bound G protein-coupled estrogen receptors [21] . Indeed, estrogen-induced suppression of Kiss1 and Tac3 in the ARC is not found in ESR1 knockout mice, but in ESR2 knockout mice [9, 11, 22] . The majority of KISS1 and TAC3 neuronal cells coexpress ESR1 [23, 24] . Based on these reports, estrogen has been conclusively shown to negatively regulate KISS1 and TAC3 gene expression via ESR1, but not ESR2. Moreover, unpublished data of Gottsch and colleagues [8] indicate that estrogen regulates dynorphin gene expression via ESR1.
In this study, to determine whether estrogen regulates dynorphin expression in the ARC, and whether the effect, if any, varies according to estrogen levels, we measured expression of Pdyn mRNA and PDYN in the ARC of female rats with different levels of sex steroids: OVX and OVX plus low or high doses of estrogen. We also examined Kiss1, KISS1, Tac3, and TAC3 expression. Furthermore, we confirmed PDYN and ESR1 colocalization in the ARC of OVX rats and low-or high-dose estrogen-treated OVX rats to determine whether estrogen acts directly on dynorphin expression and whether ERα expression in dynorphin neurons differs according to ligand concentration.
Materials and methods

Animals and treatments
Adult female Wistar-Imamichi rats (8-10 weeks of age; 160-240 g) were purchased from the Institute for Animal Reproduction (Ibaraki, Japan). The animals were maintained under illuminated conditions (14 h light and 10 h darkness, lights on at 6:00 h) in a temperaturecontrolled room (24 ± 2
• C). A standard diet and water were provided ad libitum. After confirmation of at least two regular 4 day estrous cycles by daily vaginal smears, female rats were randomly assigned into three groups: OVX, OVX plus low-dose β-estradiol (E 2 ) treatment (Low-E 2 ), and OVX plus high-dose E 2 treatment (High-E 2 ). Ovariectomy and E 2 treatments were performed under isoflurane inhalational anesthesia. For the OVX group, female rats underwent a bilateral ovariectomy via abdominal incisions at 2 weeks before blood and brain tissue sampling. For the Low-E 2 group, females were OVX and then immediately subjected to subcutaneous implantation into the right scapular region of a silastic tube [ 
Plasma sample collection
All female rats were deeply anesthetized by intraperitoneal injection of 50 mg/kg bodyweight sodium pentobarbital (Somnopentyl; Kyoritsu Seiyaku Co., Ltd, Tokyo, Japan) and 2.5 mg/kg butorphanol tartrate (Vetrphale; Meiji Seika Pharma Co., Ltd, Tokyo, Japan). Blood samples were collected from internal jugular veins in OVX, Low-E 2 , High-E 2 , Proestrus, Estrus, and Diestrus groups. Samples were centrifuged at 10,000 × g for 10 min at 4
• C. Supernatants were collected and frozen at −80 • C until hormone assays. The time periods for blood sampling ranged from 11:00 to 14:00 h.
Preparation of brain tissue samples
Immediately after blood collection, female rats in the OVX, Low-E 2 , and High-E 2 groups were intracardially perfused through the Single labeling ISH for Pdyn, Kiss1, and Tac3
To detect Pdyn, Kiss1, and Tac3 mRNA expression in the ARC, we performed nonradioactive free-floating single labeling ISH as described previously [28, 29] . Single labeling IHC for PDYN, KISS1, and TAC3
To detect PDYN, KISS1, and TAC3 in the ARC, IHC on flee-floating brain sections was performed using a peroxidaseconjugated streptavidin-biotin complex with Histofine SAB-PO kit (Cat. #424032 for PDYN and TAC3, Cat. #424022 for KISS1; Nichirei Corporation, Tokyo, Japan) in broadly the same manner as described in our previous studies [29, 31] . Brain sections were rinsed in 0.01 M PBS containing 1% (v/v) Triton X-100 (PBST) and then treated with 3% (v/v) hydrogen peroxide in PBST for 15 min at RT. After rinsing with PBST, brain sections were blocked with 5% (v/v) normal goat serum in PBST (for PDYN and TAC3) or 5% (v/v) normal rabbit serum in PBST (for KISS1) for 1 h at RT. Thereafter, brain sections for staining of PDYN were incubated with a rabbit anti-PDYN antibody (1:10000, H-021-03; Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA) for 96 h at 4
• C. For staining of KISS1 or TAC3, sections were incubated with a mouse anti-KISS1 monoclonal antibody (1:5000; a kind gift from Takeda Pharmaceutical Company Limited, Osaka, Japan) or rabbit anti-TAC3 antibody (1:5000, NB300-201; Novus Biologicals, Littleton, CO, USA) overnight at 4
• C. Specificities of the three primary antibodies were confirmed by omitting each primary antibody and antibody absorption of PDYN [32] , KISS1 [33] , and TAC3 [34] . Detailed information on the primary antibodies used are shown in Supplementary Table 1 . After washing with PBST, the sections were incubated with solution containing biotinylated secondary antibody diluted two-fold with PBST for 2 h at RT. Following rinsing, solution containing biotin/peroxidase-conjugated streptavidin was diluted two-fold with PBST and applied to the sections for 2 h at RT. For visualization, sections were reacted in 3,3 -diamino-benzidine (DAB; Sigma-Aldrich) with 0.009% hydrogen peroxide in 0.05 M Tris-HCl buffer (pH 7.6). Finally, sections were mounted on gelatincoated slides, dehydrated in ascending alcohol, cleared in xylene, and cover-slipped with EUKITT mounting regent (O. Kindler GmBh & Co., Freiburg, Breisgau, Germany).
Dual fluorescence IHC for PDYN and ESR1
Dual fluorescence IHC was used to examine colocalization of PDYN with ESR1 in rat ARCs of OVX, Low-E 2 , and High-E 2 groups. Because both PDYN and ESR1 antibodies were rabbit polyclonal antibodies, PDYN was stained first and then ESR1 was visualized using the Zenon rabbit IgG labeling kit with Alexa Fluor 568 (Z-25306; Thermo Fisher Scientific Inc.). The Zenon fragments are designed to specifically bind to the Fc portion of the primary antibody only (ESR1 in this experiment) and unbound Zenon fragments are blocked by nonspecific IgG. Antibodies labeled using the Zenon system exhibit fluorescence intensity similar to that observed for directly labeled antibody conjugates (labeled with Alexa Fluor 568 in this experiment). Sections were rinsed in PBS and reacted with blocking buffer containing 1% (w/v) BSA in PBST for 2 h at RT. Thereafter, the sections were reacted with a rabbit anti-PDYN antibody (1:5000; Phoenix Pharmaceuticals Inc.) in PBST for 96 h at 4
• C. Sections were rinsed in PBST and then incubated with donkey antirabbit IgG conjugated with Alexa Fluor 488 (1:200, A21206; Thermo Fisher Scientific Inc.) in PBST for 2 h at RT. The sections were then rinsed thoroughly in PBST. Next, immunostaining of ESR1 was performed using the Zenon rabbit IgG labeling kit (Thermo Fisher Scientific Inc.), according to the manufacturer's instructions. Zenon rabbit IgG labeling complex solution was prepared in advance. An Anti-ESR1 antibody (sc-542; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), Alexa Fluor 568 rabbit IgG labeling reagent (Component A), and blocking reagent (Component B) were mixed at a ratio of 1:3:3. Briefly, the anti-ESR1 antibody was incubated with Component A for 5 min at RT, followed by Component B for 5 min at RT. The labeling complex solution was then diluted (1:100) in PBST and applied to sections for 2 h at RT. After washing with PBS, the sections were fixed for 15 min in 4% (w/v) paraformaldehyde at RT. Finally, the sections were washed with PBS again, transferred to glass slides coated with aminosilane (Matsunami Glass, Ind., Ltd, Osaka, Japan), and enclosed in water-soluble mounting medium (DABCO mounting solution; Sigma Aldrich).
Counting mRNA-expressing and immunoreactive cell numbers All brain sections were analyzed bilaterally. Numbers of Pdyn, Kiss1, and Tac3 mRNA-expressing cells and PDYN-, KISS1-, and TAC3-ir cell bodies in the ARC were manually counted at a magnification of 20× in 12 or 13 brain sections using a BX51 microscope fitted with a DP73 digital camera (Olympus, Tokyo, Japan). To analyze PDYN-and ESR1-ir fluorescent somata, confocal images were captured using a confocal laser scanning microscope (LSM710; Carl Zeiss, Oberkochen, Germany) with a C-Apochromat × 63 (NA 1.4) oil immersion objective lens. The numbers of PDYN-or ESR1-ir cells, and PDYN/ESR1 dual-ir cells were counted in 12 brain sections. Using these data, the percentage of PDYN-ir cells expressing ESR1 was calculated by dividing the number of double-labeled cells by the total number of PDYN-ir cells and multiplying by 100. Cells were counted by an observer unaware of the animal identities and experimental groups.
Hormone assays for LH and E 2
In OVX, Low-E 2 , and High-E 2 groups, 50 μL plasma samples were assayed for LH concentrations with a rat LH radioimmunoassay kit provided by the National Hormone and Peptide Program (Torrance, CA, USA). Concentrations were expressed in terms of a National Institute of Diabetes and Digestive and Kidney Diseases standard, rat LH RP-3. The least detectable LH concentration was 0.156 ng/mL in the 50 μL of plasma samples. All samples were analyzed in duplicate in a single assay. The coefficient of intra-assay variation was 9.3%. In OVX, Low-E 2 , High-E 2 , Proestrus, Estrus, and Diestrus groups, plasma E 2 levels were measured by a competitive estradiol enzyme-linked immunosorbent assay (ELISA) kit (Cayman Chemical, Ann Arbor, MI, USA). Plasma (100 μL) and standard samples for the ELISA were extracted twice with diethyl ether (2 mL) and then dissolved in ELISA buffer (100 μL). All samples were analyzed in duplicate in a single assay, according to the manufacturer's instructions. The minimum detectable concentration was 6.6 pg/mL E 2 and the coefficient of intra-assay variation was 14.6%.
Statistical analysis
One-way analysis of variance (ANOVA) was used to determine differences in the numbers of Pdyn, Kiss1, and Tac3 mRNA-expressing cells, PDYN-, KISS1-, and TAC3-ir cells, and percentages of PDYN neurons colocalized with ESR1 among OVX, Low-E 2 , and High-E 2 groups. In the presence of significant F values, posthoc analysis was performed by the Bonferroni test. With regard to plasma levels of LH and E 2 , the Kruskal-Wallis test was used, because the assumptions were not met for ANOVA, as determined by Levene's test of equality of variances. Subsequently, we performed Steel-Dwass multiple comparisons to compare groups using the open source statistical software package R version 3.1.3. All data analyses, except for the Steel-Dwass test, were carried out using SPSS version 20 for Windows (IBM Corp., Armonk, NY, USA). P < 0.05 was considered to be statistically significant.
Results
Effect of E 2 treatment on Pdyn mRNA and PDYN expression Figure 1A shows Pdyn mRNA-expressing cells in the ARC at three representative levels (upper panels: 2.76 mm; middle panels: 3.36 mm; bottom panels: 3.86 mm posterior to the bregma [27] ) in OVX, Low-E 2 , and High-E 2 groups. The number of cells expressing Pdyn mRNA was significantly affected by E 2 treatment (F 2, 15 = 55.63, P < 0.001). Although there was no difference in the number of Pdyn mRNA-expressing cells between OVX and Low-E 2 groups, they were lower in the High-E 2 group compared with the OVX group (P < 0.001) and Low-E 2 group (P < 0.001) ( Figure 1B) . With respect to PDYN-ir cells, their distributions in the ARC at the three representative levels (as well as Pdyn mRNA) in all groups are shown in Figure 2A . E 2 manipulation changed the number of PDYN-ir cells (F 2, 18 = 31.26, P < 0.001), which was significantly increased in the Low-E 2 group compared with the OVX group (P < 0.001). Furthermore, PDYN-ir cells were reduced in the High-E 2 group compared with the Low-E 2 group (P < 0.005), but increased compared with the OVX group (P < 0.05) ( Figure 2B ). Figure 3A shows Kiss1 (upper panel) and Tac3 (lower panel) mRNAexpressing cells in the ARC at a representative level (2.76 mm posterior to the bregma [27] ) in all groups. Similar to Pdyn mRNA expression, E 2 treatment also altered the number of Kiss1 and Tac3 mRNA-expressing cells (F 2,14 = 211.01, P < 0.001; F 2,14 = 8.21, P < 0.005, respectively). Moreover, Kiss1 or Tac3 mRNA-expressing cell numbers did not differ in the Low-E 2 group compared with the OVX group. The High-E 2 group showed significant reductions of Kiss1 or Tac3 mRNA-expressing cells compared with the OVX group (P < 0.001 and P < 0.05, respectively) and Low-E 2 group (P < 0.001 and P < 0.005, respectively) ( Figure 3B and C) . Figure 4A shows KISS1 (upper panel) and TAC3 (lower panel)-ir cells at a representative level (2.76 mm posterior to the bregma [27] ). We found that E 2 treatment influenced not only mRNA expression levels, but also protein levels of KISS1 (F 2,14 = 16.47, P < 0.001) and TAC3 (F 2,15 = 27.55, P < 0.001). The numbers of KISS1 (P < 0.005) and TAC3 (P < 0.001)-ir cells were significantly greater in the Low-E 2 group compared with the OVX group. In contrast, the numbers of KISS1-and TAC3-ir cells were less in the High-E 2 group compared with the Low-E 2 group (each P < 0.001), but showed no significant difference compared with the OVX group ( Figure 4B and C) .
Effect of E 2 treatment on expression of Kiss1 and Tac3 mRNAs, and KISS1 and TAC3
Colocalization of PDYN and ESR1 in the ARC, and effects of E 2 treatments PDYN and ESR1 double-labeled cells in the ARC are shown in Figure 5A and B. The total number of PDYN-ir cells changed depending on the E 2 milieu (F 2,14 = 11.81, P < 0.005). Specifically, the Low-E 2 group had more PDYN-ir cells compared with the OVX group (P < 0.05) and High-E 2 group (P < 0.005), while there was no difference in PDYN-ir cells between the OVX and High-E 2 groups ( Figure 5C ).
The number of ESR1-ir cells was also affected by E 2 (F 2,14 = 26.11, P < 0.001), which decreased in the High-E 2 group compared with the other groups (P < 0.001) ( Figure 5D ). The number of PDYN-ir cells expressing ESR1 was also changed by E 2 treatment (F 2,14 = 13.88, P < 0.001), which was higher in the Low-E 2 group compared with the OVX group (P < 0.05) and High-E 2 group (P < 0.001) ( Figure 5E ). Furthermore, there was a significant effect of E 2 on the percentage of PDYN neurons expressing ESR1 (F 2,14 = 4.08, P < 0.05). However, posthoc analysis found no statistically significant differences among the groups ( Figure 5F ).
Plasma levels of LH and E 2
There was a significant effect of E 2 on plasma LH levels among the groups (H = 18.22, df = 2, P < 0.0001). In the Low-E 2 group, plasma LH levels were significantly decreased compared with the OVX group (P < 0.005). All rats in the High-E 2 group showed undetectable levels of LH, which were below the limit of detection (0.156 ng/mL). Thus, LH levels in the High-E 2 group were exceedingly low compared with the OVX group (P < 0.0001), although no difference was observed between the Low-E 2 and High-E 2 groups ( Figure 6A ).
Mean plasma E 2 concentrations were different among the groups (H = 23.78, df = 5, P < 0.0001). Plasma E 2 levels of Low-E 2 group were comparable with those of OVX, Proestrus, Estrus, and Diestrus groups, whereas High-E 2 group showed significantly higher (P < 0.01) plasma E 2 levels than Estrus, OVX, and Low-E 2 groups ( Figure 6B ). Although a post-hoc analysis did not detect a significant difference between High-E 2 and Diestrus groups, the plasma E 2 levels in High-E 2 group were apparently higher than those in Diestrus group ( Figure 6B ).
Discussion
E 2 suppresses Pdyn mRNA expression in the ARC of female rats
We aimed to determine whether estrogen regulates dynorphin expression in the ARC of female rats. Accordingly, we examined both mRNA and protein levels of dynorphin in the ARC of OVX, Low-E 2 , and High-E 2 groups. Consistent with a previous study [19] , we confirmed that low-dose E 2 treatment had no effect on Pdyn mRNA expression. In contrast, our observation that high-dose E 2 treatment induced notable attenuation of Pdyn mRNA-expressing cell numbers is consistent with earlier reports [2, 3, 8] . In the previous studies, the E 2 dosages were 1 mg/mL for mice and 100 μg/mL for rats, which are higher than in our Low-E 2 group (20 μg/mL). Taken together, the divergent effects of estrogen may be due to the dosage, that is, Pdyn mRNA expression is negatively controlled by E 2 at high doses, but not low doses. However, in monkeys and ewes, dynorphin gene expression in the ARC of females is thought to be evoked by estrogen [17, 18] . The species difference of Pdyn expression may reflect slightly different roles in reproductive physiology, because KNDy neurons of ewes are associated with not only the negative feedback system by E 2 but also positive feedback actions of E 2 to induce the LH surge [35] .
Regulation of dynorphin expression is dependent on E 2 levels
To our knowledge, this is the first study to quantify PDYN-ir cells in the ARC upon E 2 withdrawal and manipulation. Low-dose E 2 treatment increased PDYN-ir cells despite no changes in Pdyn mRNAexpressing cells. A reasonable explanation for the discordant mRNA and protein expression is that the low E 2 dosage had an inhibitory action on PDYN release without alteration of mRNA expression, thereby resulting in PDYN accumulation, which could be detected by IHC. This hypothesis is consistent with our KISS1 and TAC3 results in which low-dose E 2 increased KISS1-and TAC3-ir cell numbers without alteration of their mRNA levels. Because KISS and TAC3 act as stimulators of LH release, we consider that the prominent decrease of plasma LH levels in the Low-E 2 group resulted from suppression of KISS1 and TAC3 release under the low E 2 milieu.
Regarding the effect of high-dose E 2 treatment, PDYN-ir cell numbers detected by DAB staining decreased in parallel with Pdyn mRNA. This decrease indicates that a reduction of Pdyn mRNA leads to a decrease in PDYN production. However, in comparison with the OVX group, the PDYN-ir cell number slightly increased, despite a decrease in the Pdyn mRNA-expressing cell number. This result provides a potential mechanism through which an inhibitory effect of estrogen on PDYN release exists simultaneously in addition to a mechanism to suppress Pdyn mRNA expression. However, PDYN-ir cell numbers analyzed by fluorescence IHC were the same in the OVX and High-E 2 groups. Thus, we cannot exclude the possibility that the apparent increase was due to differences in DAB and fluorescence stainings.
Effect of E 2 on KISS1 and TAC3
The extent of the reductions of mRNA-expressing cells by highdose E 2 treatment was different for each gene. The High-E 2 group had a markedly lower number of Kiss1 mRNA-expressing cells (less than half) compared with the OVX and Low-E 2 groups, whereas the High-E 2 group had a modestly lower number of Tac3 mRNAexpressing cells than the other groups. Pubertal lack of E 2 has been reported to increase Kiss1 mRNA expression, while Tac3 expression is unaffected [12] . Furthermore, lower E 2 manipulation is required for Kiss1 suppression compared with Tac3 [12] . Combined with our results, these findings suggest that Kiss1 mRNA expression is more sensitive to E 2 compared with Tac3 expression. In this context, Pdyn gene expression presumably responds sensitively to E 2 stimuli, as well as Kiss1, because Pdyn mRNA-expressing cell numbers had decreased sharply compared with Tac3 mRNA-expressing cells.
We also found that the number of KISS1-and TAC3-ir cells varied in the same manner with E 2 levels. However, a previous report found that E 2 induces an increase of TAC3-ir cells, but not KISS1-ir cells, indicating that these peptides are differentially regulated by E 2 [16] . Because Kiss1 may be more sensitive to E 2 than Tac3, the reason for this inconsistency may again be related to the E 2 dosage. For E 2 replacement, the authors of the previous study used silicone implants containing E 2 (100 μg/mL) [16] , which enables female rats to have circulating E 2 levels equivalent to the proestrous phase [3] . As the authors described, the dose was at a physiological level, but still slightly higher than that in the Low-E 2 group in our study, because the plasma E 2 level achieved with low E 2 replacement in our study was apparently lower than that in the proestrous stage. Therefore, the finding in the previous study may result from inhibition of Kiss1 mRNA levels by E 2 .
Effects of E 2 on PDYN, KISS1, and TAC3 in physiological states
We confirmed that low E 2 treatment resulted in plasma E 2 levels equivalent to those in estrous and diestrous phases, indicating that the Low-E 2 model apparently mimics the physiological states except for proestrus. Therefore, endogenous estrogen may control the release of each peptide of KNDy neurons in the ARC under physiological conditions. There was no difference in plasma E 2 concentrations between OVX and Low-E 2 groups. Therefore, the absence of ovaries for 2 weeks may not cause complete depletion of E 2 as previous study [25] .
High-dose E 2 -treated rats displayed high levels of plasma E 2 , which were comparable to those in the proestrous phase and assumed to induce the LH surge as reported previously [28, 36] . Thus, it appears likely that the High-E 2 model mimics the proestrous state. Under proestrous conditions, endogenous estrogen may suppress mRNA expression in KNDy neurons of the ARC, suggesting that the GnRH pulse generator itself is least active at proestrus. A reason for the undetectable level of plasma LH in High-E 2 group is that the time point of day for blood sampling (11:00-14:00 h) was earlier than the LH surge (after 14:00 h [36] ).
E 2 signaling via ESR1 for dynorphin expression
In both OVX and Low-E 2 groups, approximately 80% of PDYN-ir cells coexpressed ESR1. In the High-E 2 group, approximately 60% of PDYN-ir cells coexpressed ESR1, although there tended to be a small decrease in percentage of colocalization between PDYN and ESR1. Thus, it is tenable that dynorphin is directly regulated by E 2 via ESR1 regardless of estrogen levels.
However, we noted the possibility that increased protein levels of PDYN may result from inhibition of PDYN release by low E 2 . It appears plausible that low E 2 affects the processes of axonal transport and/or exocytosis in dynorphin neurons. Indeed, estrogen alters the expression of genes encoding motor transport proteins (namely kinesin, dynactin, and dynein) and a gene associated with exocytosis (a Ca 2+ -dependent activator protein for secretion) in the pontine midbrain of female macaques [37] and the hypothalamus of female guinea pigs [38] , respectively. To determine whether such gene expression changes are responsible for the increase in PDYN, further studies on the detailed molecular and cellular mechanisms will be necessary. Because more than half of PDYN-ir cells in the ARC expressed ESR1 in the High-E 2 group, Pdyn mRNA expression was probably modulated by high-dose E 2 via ESR1. In support of this notion, Gottsch et al. demonstrated that, in both ESR1 null female mice and female mice with an ESR1 allele that cannot bind estrogen response element (ERE) sites, pharmacological E 2 does not reduce Pdyn mRNA expression in the ARC [8] . This result indicates that pharmacological E 2 negatively regulates Pdyn mRNA expression in an ERE-dependent manner, and ERE-independent signaling is not required for high-dose E 2 -stimulated expression of Pdyn. The small decrease in PDYN and ESR1 colocalization in the High-E 2 group may be attributable to E 2 -induced downregulation of ESR1 expression. Although it is generally assumed that E 2 downregulates ESR1, there was a dose-dependent effect. The reduction in ESR1 expression was caused by high-dose E 2 (pharmacological dose) but not low-dose E 2 (physiological dose), as reported previously [39] [40] [41] . In contrast, membrane ESR1, which mediates nongenomic signaling, in the ARC of female rats is increased by a physiological dose of E 2 and decreased by a pharmacological dose of E 2 [41] . Thus, different estrogen receptor signaling that is dependent on the E 2 dose may partly contribute to different regulation of dynorphin expression by low or high doses of E 2 .
In summary, our results show that low-dose E 2 treatment increases the PDYN-ir cell number, but does not affect Pdyn gene expression, whereas high-dose E 2 treatment decreases the expression levels of both the dynorphin gene and protein. This finding suggests that low-dose E 2 may inhibit PDYN release without affecting Pdyn gene expression, whereas high-dose E 2 may suppress Pdyn mRNA expression, resulting in low PDYN levels. Such changes regulated by E 2 were similarly observed in the expression of Kiss1, KISS1, Tac3, and TAC3. Furthermore, the majority of PDYN-ir cells coexpress ESR1 regardless of E 2 levels. Taken together, estrogen regulates dynorphin as well as KISS1 and TAC3, and the action of estrogen in dynorphin neurons may change according to E 2 levels.
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